Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023)

ProQR Therapeutics' Non-Current Debt history spans 4 years, with the latest figure at $4.6 million for Q4 2023.

  • On a quarterly basis, Non-Current Debt rose 5.98% to $4.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.6 million, a 5.98% increase, with the full-year FY2023 number at $4.6 million, up 5.98% from a year prior.
  • Non-Current Debt hit $4.6 million in Q4 2023 for ProQR Therapeutics, up from $4.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for PRQR hit a ceiling of $45.0 million in Q4 2021 and a floor of $4.4 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $18.3 million across 4 years, with a median of $12.0 million in 2020.
  • Biggest five-year swings in Non-Current Debt: soared 133.03% in 2021 and later plummeted 90.31% in 2022.
  • Tracing PRQR's Non-Current Debt over 4 years: stood at $19.3 million in 2020, then skyrocketed by 133.03% to $45.0 million in 2021, then crashed by 90.31% to $4.4 million in 2022, then rose by 5.98% to $4.6 million in 2023.
  • Business Quant data shows Non-Current Debt for PRQR at $4.6 million in Q4 2023, $4.4 million in Q4 2022, and $45.0 million in Q4 2021.